| Evotec (52)

Rising antimicrobial resistance challenges our ability to combat bacterial infections. The problem is acute for tuberculosis (TB), the leading cause of death from infection before COVID-19.

Here, we developed a framework for multiple pharmaceutical companies to share proprietary information and compounds with multiple laboratories in the academic and government sectors for a broad examination of the ability of β-lactams to kill Mycobacterium tuberculosis (Mtb). In the TB Drug Accelerator (TBDA), a consortium organized by the Bill & Melinda Gates Foundation, individual pharmaceutical companies collaborate with academic screening laboratories.

In this paper we describe strategies used to prioritize thousands of β-lactams from multiple companies into a small test set for further characterization.
In a striking contrast to historical expectation, 18% of β-lactams screened were active against Mtb, many without a β-lactamase inhibitor.
One potent cephaloporin was active in Mtb-infected mice.

The steps outlined here can serve as a blueprint for multiparty, intra- and intersector collaboration in the development of anti-infective agents.

GET THE PAPER

Science Pool

Evotec

Recent Posts

Formulating your Way to Successful Toxicology Studies

An Overview of Safety Assessment Services

Read about 3D Cellular Models in Prediction of Tox and Kidney Disease

Free Guide: Everything you Need to Know about ADME

Whitepaper: An Integrated Approach to Drug Abuse Liability

Want to Know More about Transcriptomics in Tox Prediction?

Find the Fastest Route to the Clinic

Read our Pathology Fact Sheet

Learn More about Toxicology in our Science Pool

Identification of β-Lactams Active Against Mycobacterium Tuberculosis